PHASE II STUDY PS341 ALONE OR COMB W/ IRINOTECAN IN PATIENTS W/ ADENOCARCINOMA

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 目标是：（1）确定伊立替康和PS 341组合在患有先前未经治疗的胃食管连接部或胃腺癌的患者中的响应率;（2）确定PS 341在患有先前未经治疗的胃食管连接部或胃腺癌的患者中的响应率、接受PS 341单独或与伊立替康组合的患者的毒性和从毒性的恢复;和（3）在用PS 341处理之前和之后对活检标本进行基因芯片分析以确定基因表达模式的变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Aims are: (1) to determine response rate for combination of irinotecan and PS341 in patients with previously untreated adenocarcinoma of gastroesophageal juntion or stomach; (2) to determine response rate for PS341 in patients with previously treated adenocarcinoma of the gastrophageal junction or stomach, the toxicities and recovery from toxicities for patients recieving PS341 alone or in combincation with irinotecan; and (3) to perform GeneChip analysis on biopsy specimens prior to and subsequent to treatment with PS341 to determine changes in patterns of gene espression.